Table 1.
Baseline characteristics and comparison stratified by monocarboxylate transporter (MCT) 1 score.
| Variables | MCT1 Score 0, n = 21 |
MCT1 Score 1, n = 35 |
MCT1 Score 2, n = 53 |
P between Groups |
|---|---|---|---|---|
| Sex | ||||
| Male, n (%) | 12 (57.1) | 21 (60.0) | 27 (50.9) | 0.689 |
| Age, median (IQR) years | 61 (56–69) | 66 (56–73) | 66 (56–73) | 0.866 |
| T-Class | 0.109 | |||
| T1–2, n (%) | 3 (14.3) | 9 (25.7) | 15 (28.3) | |
| T3, n (%) | 13 (61.9) | 17 (48.6) | 16 (30.2) | |
| T4, n (%) | 5 (23.8) | 9 (25.7) | 22 (41.5) | |
| N-Class | 0.530 | |||
| N0, n (%) | 3 (14.3) | 5 (14.3) | 12 (22.6) | |
| N1–2, n (%) | 18 (85.7) | 30 (85.7) | 41 (77.4) | |
| M-Class | 0.860 | |||
| M0, n (%) | 13 (61.9) | 24 (68.6) | 34 (64.2) | |
| M1, n (%) | 8 (38.1) | 11 (31.4) | 19 (35.8) | |
| Stage | 0.950 | |||
| I-II, n (%) | 2 (9.5) | 5 (14.3) | 5 (9.4) | |
| III, n (%) | 11 (52.4) | 19 (54.3) | 29 (54.7) | |
| IV, n (%) | 8 (38.1) | 11 (31.4) | 19 (35.8) | |
| Grade | ||||
| 1, n (%) | 17 (81.0) | 28 (80.0) | 40 (75.5) | 0.825 |
| 2, n (%) | 4 (19.0) | 7 (20.0) | 13 (24.5) | |
| Tumor location | 0.033 | |||
| Ileum, n (%) | 18 (85.7) | 32 (91.4) | 53 (100) | |
| Jejunum, n (%) | 3 (14.3) | 3 (8.6) | 0 | |
| Somatostatin analogue treatment | 0.391 | |||
| Yes, n (%) | 12 (57.1) | 16 (45.7) | 32 (60.4) | |
| Chemotherapy | 0.818 | |||
| No, n (%) | 16 (76.2) | 28 (80.0) | 45 (84.9) | |
| Preoperative, n (%) | 1 (4.8) | 2 (5.7) | 2 (3.8) | |
| Postoperative, n (%) | 4 (19.0) | 4 (11.4) | 4 (7.5) | |
| Multiple primary tumors | 0.403 | |||
| Yes, n (%) | 8 (40.0) | 8 (22.9) | 15 (28.8) | |
| P-CgA | ||||
| ≥3 nmol/L, n (%) | 16 (88.9) | 24 (85.7) | 43 (87.8) | 0.945 |
| Median (IQR) nmol/L | 8.5 (4.7–15.0) | 6.4 (3.6–13.5) | 4.8 (3.4–15.0) | 0.587 |
| dU-5-HIAA | ||||
| ≥42 µmol/L, n (%) | 10 (66.7) | 18 (69.2) | 21 (48.8) | 0.193 |
| Median (IQR) µmol/L | 56 (37–199) | 96 (27–149) | 40 (25–169) | 0.632 |
P-CgA, plasma chromogranin A; dU-5-HIAA, 24 h urine hydroxyindoleacetic acid.